Compounding Chief Departing US FDA After Leading Office Through 'Tumultuous Times'

Julie Dohm, the senior science advisor for compounding who serves as the US FDA lead on compounding and has helped to spearhead a wide range of initiatives to enforce the Drug Quality and Security Act (DQSA,) will be leaving the agency on March 29. She has been credited with her steady leadership in guiding the agency's compounding office through a difficult time.

Dohm will be joining the law firm of Covington & Burling. A replacement at FDA has not yet been announced.